TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: wound assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of abdominal lymphoadenomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological changes in liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total PCA tramadol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Bone Level (MBL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in feasible surgery at baseline to actual surgery at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in the incidence of arrhythmic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of edema fluid in the arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of edema fluid in the legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in circumference of the arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic resistance levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nasal carriage rates of pneumococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Carriage of vaccine serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1-year increase in serum Mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in St Mark's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ICIQ-UI-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FIQL scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate to terazosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain during sessions
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of dyslipidemia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of proteinuria events
Endpoint domain: Adverse events/effects
Primary endpoint: viral load decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postprandial glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Somnolence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation to perform activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decrease in physically aggressive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in neutral/prosocial behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPT-M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoral temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FES ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic preparation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Solid stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in omega‐6 to omega‐3 fatty acid ratios in RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in OSDI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of deep CBD cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean time to successful deep CBD cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mild to moderate pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: anesthetic success in the first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for ASA, SA and paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for ASA, SA and paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax for ASA, SA and paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved functional abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ultrasound assessment of gastric volume reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to death or rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in plasma IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diffusive clearance of cytokines (IL-6, IL-8, IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative albumin loss into the effluent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: LV end‐diastolic pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COPM-Performance score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: COPM-Satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to first fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to second fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first fall-related GP-consultation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first fall-related ED-visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acne score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sex hormone‐binding globulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pathological progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: headache response at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache response at 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volumetric wear rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate after Ahmed tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean longitudinal early diastolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow propagation velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean longitudinal displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve complete block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glaucomatous field progression
Endpoint domain: Mortality/survival
Primary endpoint: time of bleeding stop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success rates for VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates for FBRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving excellent recovery at three months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fewer symptom-free days in the prior two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma-related hospitalization in the prior year
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative prevalence of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SCORAD ≥ 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SPT sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: occurrence of meconium contaminated amnionic fluid and premature delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: weight and Apgar grade of newborn babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete control of acute emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No emesis and no nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of nausea grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent time spent at glucose <70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major GIB events
Endpoint domain: Adverse events/effects
Primary endpoint: Life-threatening GIB events
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional cost per child
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Enteral tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: End-tidal carbon dioxide concentrations (ETCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Minute volume of ventilation (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Persistent wheeze or asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infections of the lower respiratory tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Drug-related problems (DRPs) identified during patient interviews
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendations for drug change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation of recommendations for drug change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistence of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Gain (WG) > or = 10 g/kg/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case Fatality Rate (CFR)
Endpoint domain: Mortality/survival
Primary endpoint: Increased probability of being an anxiety case
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of eyes gaining 5 or more logMAR letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute improvement in BCVA at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent sickness absence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: chronic neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of predicted PEF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak creatine kinase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: drug liking E(max)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: resuscitation knowledge and skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the St Louis Testosterone Deficiency Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: sore throat pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difficulty swallowing relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swollen throat relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WHtR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dominant fibroid diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of new fibroid formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalized onset of breast development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Normalized onset of testicular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Progression of carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: overall glycemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin secretion in response to meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients who experienced flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laycarer confidence with injection administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement in detection of apnea and hypopnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day shock reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum thyrotrophin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of care concordance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: change in fat mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in fat-free mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute fat-free mass gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NBNA summary score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum postprandial TG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quality of life measured by IPSS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to complete QCS vs. MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric and duodenal ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of hives
Endpoint domain: Adverse events/effects
Primary endpoint: supplemental opioid requirement
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in emotion regulation difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in self-compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported mesalamine adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved survival of insulin-treated patients
Endpoint domain: Mortality/survival
Primary endpoint: Dialysate levels of cancer antigen 125 (CA125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HDL3 cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid concentrations outcomes
Primary endpoint: plasma apo B concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid concentrations outcomes
Primary endpoint: mean minimum lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Stressor Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeding interaction quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Asthma intensive care unit admission
Endpoint domain: Mortality/survival
Primary endpoint: High SABA use
Endpoint domain: Physiological/clinical
Primary endpoint: PPVT-R score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sufficient physical activity after one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune depression in T lymphocyte subsets and natural killer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at total body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ECG modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of 6MP, thioxanthine, and MeMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of thiouric acid and RBC‐MeTIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bronchospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of aminophylline use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway tract spasm-free duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean AUC0-24 h-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal system disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in in-office visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Mental composite score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical composite score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean plasma exposure of paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-time needling success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: middle distance running performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of therapeutic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PCSK9 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: YGTSS Total Tic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YGTSS impairment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: APTT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: swallowing disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of short sharp pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intraoperative glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes